Search company, investor...
Armetheon company logo

Armetheon

armetheon.com

Founded Year

2011

Stage

Merger | Merged

Total Raised

$31.3M

About Armetheon

Armetheon is a privately held San Francisco Bay area based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced, successful biotech entrepreneurs and drug developers with funding from AshHill Biomedical investments (http://www.ashhill.net) and Atheneos Capital (http://www.atheneoscapital.com). Armetheon's two late-stage small molecule drug candidates are for use in the areas of oral anticoagulation and atrial fibrillation.

Headquarters Location

325 Sharon Park Drive #303

Menlo Park, California, 94025,

United States

650-646-2898

Missing: Armetheon's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Armetheon's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Armetheon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Armetheon is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Armetheon Patents

Armetheon has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/4/2013

1/24/2017

Cardiac arrhythmia, Calcium channel blockers, Cardiac anatomy, Antiarrhythmic agents, Cardiac electrophysiology

Grant

Application Date

2/4/2013

Grant Date

1/24/2017

Title

Related Topics

Cardiac arrhythmia, Calcium channel blockers, Cardiac anatomy, Antiarrhythmic agents, Cardiac electrophysiology

Status

Grant

Latest Armetheon News

Oral Anticoagulants Market is Expected to Witness Rapid Growth by 2028 | Daiichi Sankyo, Armetheon, Aspen, Boehringer Ingelheim, Johnson & Johnson, Sanofi, Pfizer Inc., AstraZeneca and Others

Mar 2, 2021

| Daiichi Sankyo, Armetheon, Aspen, Boehringer Ingelheim, Johnson & Johnson, Sanofi, Pfizer Inc., AstraZeneca and Others VALLEY COTTAGE, N.Y. – Impact of COVID-19 on the Healthcare Industry The COVID-19 pandemic has causedsevere impacts on the global economy at various levels and which can be seen onthe Healthcare industry as well. The thriving market of health care researchand development is expected to exhibit a steep decline in the sales during thelockdown period owing to the shutdown of the manufacturing units, acuteshortage in the supply of raw materials and absence of potential manpower. Itcan be deduced from the current situations brought about by the pandemic thatthe production, and supply chain activities have experienced minor hurdles.However, the market is projected to gradually recover post-COVID-19, which willpresent attractive opportunities for sales across various regions of the worldin the following years. Future Market Insights (FMI) adopteda multidisciplinary approach during the pandemic-era to focus on the growth anddevelopment of the OralAnticoagulants Market . The study features insights on the current growthdynamics and the major revenue reforms prevailing in the market as along withthe key takeaways over the forecast. The team of analysts at Future MarketInsights are focussing on research and market study to produce different OralAnticoagulants Market forecasts and predictions at both national andinternational levels. They have considered several leads of informationpertaining to the industry like market figures and merger estimations to assessand produce reliable and informative insights on the Oral AnticoagulantsMarket. To remain ‘ahead’ of your competitors, Ask aQuestion >> https://www.futuremarketinsights.com/ask-question/rep-gb-6587 Key Players The writer will create content on thegeneral strategies of market players. And then will write the key players inthe market are: The Medicines Company, Urigen Pharmaceuticals, Cellceutix, Eisai,Sagent Pharmaceuticals, Daiichi Sankyo, Armetheon, Aspen, Boehringer Ingelheim,Johnson & Johnson, Sanofi, Pfizer Inc., AstraZeneca and Others Segmentation The report provides insights on the important highlights and currenttrends prevailing in the market. This helps the readers to gain a deeperunderstanding and form an unbiased opinion on the market. Numeroussegmentations have been provided for this market based on: Segmentation byDisease Indication: Arterial and venous thrombosis Fullin-depth analysis of the parent market The analysts at FMI are dedicated toprovide insights after extensive research and study. The study also includesestimations, projections and evaluation of the market dynamics. Importantchanges in market dynamics The report has beencreated after detailed and exhaustive studies by the analysts at FMI takingseveral factors into consideration like monetary, ecological, social,mechanical, and political status of a particular demography. They study the keydata to assess the revenue and production of manufacturers across variousregions. The report also covers an in-depth analysis ofthe key changes in market dynamics in the recent past and the near future. Segmentationdetails of the market Emerging segments and regional markets Queries Solved What are the key segments andsub-segments in the market? What are the key drivers, restraints,opportunities, and challenges of the Oral Anticoagulants Market in theHealthcare Industry, and how they are expected to impact the market? What are the attractive investmentopportunities within the Oral Anticoagulants Market in the Healthcare Industry? What is the Oral Anticoagulants Marketin the Healthcare Industry size at the regional and country-level? What are the key market playersfocusing on? What are the strategies for growthadopted by the key players in Oral Anticoagulants Market in the HealthcareIndustry? What are the recent trends in OralAnticoagulants Market in the Healthcare Industry? (M&A, partnerships, newproduct developments, expansions)? What are the challenges to the OralAnticoagulants Market in the growth of the Healthcare Industry? What are the key market trendsimpacting the growth of the Oral Anticoagulants Market in the HealthcareIndustry? To receive extensive list of importantregions, ask for TOC here >>  https://www.futuremarketinsights.com/toc/rep-gb-6587 Table of Content MarketBackground    Reasons to Buythe report We provide authentic and detailed ananalysis on various market trends to enable businesses to make informed and beneficialdecisions to attain competitive edge over key players. Our analysts provide detailed marketsegmentation along with meaningful insights and extensive reports that othercompanies fail to include. The report includes accurate analysisof the market and the current developing trends affecting the growth. FMI speaks tostakeholders across the spectrum, including C-level executives, distributors,product manufacturers, industry experts. This ensures that the data collected is fromhighly reliable sources. Explore Wide-ranging Coverage of FMI’s HealthcareLandscape Transradial Closure Devices Market – According to Future Market Insights (FMI), the demand from hospitals,independent catheterization centers, and healthcare clinics will continuerising. Spurred by this, the global transradial closure devices market is setto grow by 6.5% CAGR during the forecast period from the year 2020 to 2030. In Vitro FertilizationBanking Services Market – The in vitro fertilization banking servicesmarket, despite undergoing a temporary period of lull due to COVID-19 outbreak,is likely to have an impressive growth trajectory between 2020 and 2030. Cryopreservationfor In-vitro Fertilization (IVF) Market – According to analysis by Future Market Insights (FMI), cryopreservationfor IVF market surpassed a valuation of US$ 339 million in 2019. Themarket is set to reflect an impressive 10.2% CAGR through 2030. About FMI        Future Market Insights (FMI) is a leading provider of marketintelligence and consulting services, serving clients in over 150countries. FMI  isheadquartered in Dubai, the global financial capital, and has delivery centersin the U.S. and India. FMI’s latest  marketresearch reports  and industry analysis help businesses navigatechallenges and make critical decisions with confidence and clarity amidstbreakneck competition. Our customized and syndicated market research reportsdeliver actionable insights that drive sustainable growth. A team of expert-ledanalysts at FMI continuously tracks emerging trends and events in a broad rangeof industries to ensure that our clients prepare for the evolving needs oftheir consumers. ContactUs

Armetheon Frequently Asked Questions (FAQ)

  • When was Armetheon founded?

    Armetheon was founded in 2011.

  • Where is Armetheon's headquarters?

    Armetheon's headquarters is located at 325 Sharon Park Drive, Menlo Park.

  • What is Armetheon's latest funding round?

    Armetheon's latest funding round is Merger.

  • How much did Armetheon raise?

    Armetheon raised a total of $31.3M.

  • Who are the investors of Armetheon?

    Investors of Armetheon include Espero Pharmaceuticals, Hercules BioVentures Partners, Capital TEN II, Atheneos Ventures, AshHill Investments and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.